Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Q2 2013/14 Earnings Presentation
13 slides from Elekta Ab Class B's earnings presentation, 2013
Slide 1: Elekta Q2 report 2013/14
Elekta Q2 report 2013/14 Tomas Puusepp, President and CEO Håkan Bergström, CFO 1
Slide 2: Growth strategy continues to be successful
Growth strategy continues to be successful • Order bookings up 10*% in Q2 – Strong growth in Europe and North America • Net sales up 10*% in H1 • Investment program to support long-term growth – MR Linac – Atlanta and Beijing LINC opened • EBITA of SEK 555** (599) M – Up 8% Y/Y excluding negative cu
Slide 3: Technology leader
Technology leader Versa HD™ Esteya® MR Linac 3
Slide 4: Market leading treatment planning solution
Market leading treatment planning solution Monaco® Focal 4D FocalPRO Monaco® 5.0 • Single versatile platform FocalSIM • 510(k) approved in November • Unified, consolidated, powerful ERGO++ XIO Oncentra® ABAS
Slide 5: North and South America
Regional overview North and South America • North America - order bookings up 21%* in Q2 – Growing faster than market – Good momentum on Versa HD™ – Atlanta LINC opened – Increased reimbursement decided • South America – Fully committed to supply modern cancer care in the region – Brazil procurement
Slide 6: Europe, Middle East and Africa
Regional overview Europe, Middle East and Africa • Strong order bookings, up by 32%* in Q2 • Established markets – Good growth in all territories – Especially strong in: – Scandinavia – France – Versa HDTM has good momentum – First patients treated with Esteya® • Emerging markets – Strong growth *Ba
Slide 7: Asia Pacific
Regional overview Asia Pacific • Order bookings decreased 7%* in Q2 – Confident of the performance for the full year • Strong trend in Japan – Good development with the Toshiba collaboration • Good development in China – Initiative in place for RT expansion – Beijing LINC opened • Change of import r
Slide 8: Strong order bookings and good deliveries
Strong order bookings and good deliveries • Order growth 10%* in Q2 • Net sales increased by 10%* in H1 – Strong deliveries in all regions • Gross margin at 43% (45) – Currency impact, US medical device tax and lower share of Leksell Gamma Knife • EBITA** of SEK 555 M (599) – Currency effect SEK -90
Slide 9: Volatility on currency markets
Volatility on currency markets • Estimated currency effect for 2013/14 – Net sales: -3 percentage points SEK M FX exposure – EBITA: -5 percentage points 4 600 Operating expenses Revenues 3 600 • Volatility on currency markets. End of 2 600 October changes (Y/Y) 1 600 – USD: -4% - GBP: -6% 600 – JPY:
Slide 10: Strong cash flow for the remainder of the year
Strong cash flow for the remainder of the year • Cash flow from operating activities SEK 282 M in Q2 • Cash flow after continuous investments SEK 61 M in Q2 • Investments increased by SEK 200 M in H1 to support future growth – R&D, MR Linac project – Training and education centers • Seasonality in w
Slide 11: Elekta's strategy for sustainable profitable growth
Elekta’s strategy for sustainable profitable growth • Technology leadership – increased activity within product development – Versa HDTM – MR linac • Emerging markets – Availability, training and education • Cancer incidence is growing 11
Slide 12: Outlook reiterated
Outlook reiterated • For the fiscal year 2013/14, net sales is expected to grow by more than 10%* • EBITA is expected to grow by approximately 10%* • Currency is estimated to have a negative impact of about 5 percentage points on EBITA growth compared to FY 2012/13 * In local currencies 12
Slide 13: Human Care Makes the Future Possible
Human Care Makes = the Future Possible